Reference(s)
Click here to return to the Reference Table

Cancer type: Prostate


HGF/SF expression

Reference Number: 119
Zhu, X. & Humphrey, P. A. Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology 56, 1071-4 (2000).
PubMed link      E-mail link

Reference Number: 248
Nakashiro K, Hayashi Y, Oyasu R. Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue. Oncol Rep 10:1149-53 (2003).
PubMed link      E-mail link

Reference Number: 325
MacDougall CA, Vargas M, Soares CR, Holzer RG, Ide AE, Jorcyk CL, Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c. Prostate 64,139-48 (2005)
PubMed link      E-mail link

Reference Number: 326
Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, Cao B, Tsarfaty G, Wang LM, Hay R, Vande Woude GF Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 24, 101-6 (2005)
PubMed link      E-mail link

Reference Number: 363
Forbs D, Thiel S, Stella MC, Sturzebecher A, Schweinitz A, Steinmetzer T, Sturzebecher J, Uhland K. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol. 27, 1061-70 (2005)
PubMed link      E-mail link

Reference Number: 371
Nagakawa O, Yamagishi T, Akashi T, Nagaike K, Fuse H. Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer. Prostate 66, 447-52 (2006)
PubMed link      E-mail link

Reference Number: 372
Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene. 25, 2367-78 (2006)
PubMed link      E-mail link

Reference Number: 373
Wells CM, Ahmed T, Masters JR, Jones GE. Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering. Cell Motil Cytoskeleton 62, 180-94 (2005)
PubMed link      E-mail link

Reference Number: 376
Hurle RA, Davies G, Parr C, Mason MD, Jenkins SA, Kynaston HG, Jiang WG. Hepatocyte growth factor/scatter factor and prostate cancer: a review. Histol Histopathol. 20, 1339-49 (2005)
PubMed link      E-mail link

Reference Number: 377
Nagakawa O, Yamagishi T, Fujiuchi Y, Junicho A, Akashi T, Nagaike K, Fuse H. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer. Eur Urol. 48, 686-90 (2005)
PubMed link      E-mail link

Reference Number: 378
Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE. Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am J Pathol. 167, 255-66 (2005)
PubMed link      E-mail link

Reference Number: 379
Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J. 390, 125-36 (2005)
PubMed link      E-mail link

Reference Number: 380
Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett. 579, 1945-50 (2005)
PubMed link      E-mail link

Reference Number: 381
Fan S, Gao M, Meng Q, Laterra JJ, Symons MH, Coniglio S, Pestell RG, Goldberg ID, Rosen EM. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 24, 1749-66 (2005)
PubMed link      E-mail link

Reference Number: 385
Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 66, 794-802 (2006)
PubMed link      E-mail link

Reference Number: 386
Hashem M, Essam T. Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer. J Egypt Natl Canc Inst. 17, 114-20 (2005)
PubMed link      E-mail link

Reference Number: 475
Humphrey PA, Halabi S, Picus J, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer. 4, 269-74 (2006)
PubMed link      E-mail link

Reference Number: 587
Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Namba Y, Kishikawa H, Takahara S, Ichikawa Y. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels. Prostate Cancer Prostatic Dis. 11, 258-63 (2008)
PubMed link      E-mail link

Reference Number: 588
Sanders AJ, Parr C, Mason MD, Jiang WG. Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro. Int J Mol Med. 20, 613-9 (2007)
PubMed link      E-mail link

Reference Number: 631
Shukla CJ, Pennington CJ, Riddick AC, Sethia KK, Ball RY, Edwards DR. Laser-capture microdissection in prostate cancer research: establishment and validation of a powerful tool for the assessment of tumour-stroma interactions. BJU Int. 101, 765-74 (2008)
PubMed link      E-mail link

Reference Number: 654
Ye L, Lewis-Russell JM, Sanders AJ, Kynaston H, Jiang WG. HGF/SF up-regulates the expression of bone morphogenetic protein 7 in prostate cancer cells. Urol Oncol. 26, 190-7 (2008)
PubMed link      E-mail link

Reference Number: 688
Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, Shariat SF. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res. 14, 7385-90 (2008)
PubMed link      E-mail link

Reference Number: 720
Yasuda K, Nagakawa O, Akashi T, Fujiuchi Y, Koizumi K, Komiya A, Saiki I, Fuse H. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. Prostate 69, 346-51 (2009)
PubMed link      E-mail link

Reference Number: 727
Wells CM, Whale AD, Parsons M, Masters JR, Jones GE. PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion. J Cell Sci. 123(Pt 10), 1663-73 (2010)
PubMed link      E-mail link

Reference Number: 927
Wang Y, Yue D, Li K, Liu YL, Ren CS, Wang P. The role of TRPC6 in HGF-induced cell proliferation of human prostate cancer DU145 and PC3 cells. Asian J Androl. 12, 841-52 (2010)
PubMed link      E-mail link

Reference Number: 930
Ahmed T, Shea K, Masters JR, Jones GE, Wells CM. A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell Signal. 20, 1320-8 (2008)
PubMed link      E-mail link

Reference Number: 941
Bright MD, Garner AP, Ridley AJ. PAK1 and PAK2 have different roles in HGF-induced morphological responses. Cell Signal. 21, 1738-47 (2009)
PubMed link      E-mail link

Reference Number: 1284
Nishida S, Hirohashi Y, Torigoe T, Inoue R, Kitamura H, Tanaka T, Takahashi A, Asanuma H, Masumori N, Tsukamoto T, Sato N. Prostate cancer stem-like cells/cancer-initiating cells have an autocrine system of hepatocyte growth factor. Cancer Sci. 104, 431-6 (2013)
PubMed link      E-mail link

Reference Number: 1622
Martin TA, Mason MD, Jiang WG. HGF and the regulation of tight junctions in human prostate cancer cells. Oncol Rep. 32, 213-24 (2014)
PubMed link      E-mail link

Reference Number: 1850
Cecchi F, Lih CJ, Lee YH, Walsh W, Rabe DC, Williams PM, Bottaro DP. Expression array analysis of the hepatocyte growth factor invasive program. Clin Exp Metastasis. 32, 659-76 (2015)
PubMed link      E-mail link

Met expression

Reference Number: 120
Humphrey, P. A. et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147, 386-96 (1995).
PubMed link      E-mail link

Reference Number: 121
Knudsen, B. S. et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 60, 1113-7 (2002).
PubMed link      E-mail link

Reference Number: 122
Pisters, L. L. et al. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 154, 293-8. (1995).
PubMed link      E-mail link

Reference Number: 123
Tsuka, H. et al. Expression of c-MET/HGF receptor mRNA and protein in human non-malignant and malignant prostate tissues. Int J Oncol 13, 927-34 (1998).
PubMed link      E-mail link

Reference Number: 248
Nakashiro K, Hayashi Y, Oyasu R. Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue. Oncol Rep 10:1149-53 (2003).
PubMed link      E-mail link

Reference Number: 249
van Leenders G, van Balken B, Aalders T, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. Prostate 51:98-107 (2002).
PubMed link      E-mail link

Reference Number: 284
Strohmeyer D, Strauss F, Rossing C, Roberts C, Kaufmann O, Bartsch G, Effert P. Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anticancer Res 24, 1797-804 (2004)
PubMed link      E-mail link

Reference Number: 326
Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, Cao B, Tsarfaty G, Wang LM, Hay R, Vande Woude GF Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 24, 101-6 (2005)
PubMed link      E-mail link

Reference Number: 372
Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene. 25, 2367-78 (2006)
PubMed link      E-mail link

Reference Number: 376
Hurle RA, Davies G, Parr C, Mason MD, Jenkins SA, Kynaston HG, Jiang WG. Hepatocyte growth factor/scatter factor and prostate cancer: a review. Histol Histopathol. 20, 1339-49 (2005)
PubMed link      E-mail link

Reference Number: 379
Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J. 390, 125-36 (2005)
PubMed link      E-mail link

Reference Number: 380
Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett. 579, 1945-50 (2005)
PubMed link      E-mail link

Reference Number: 538
Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res. 67, 967-75 2007
PubMed link      E-mail link

Reference Number: 731
Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, Berghuis B, Daugherty J, Grabinski T, Toro J, Giambernardi T, Skinner RS, Gross M, Hudson E, Kort E, Lengyel E, Ventura A, West RA, Xie Q, Hay R, Woude GV, Cao B. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol. 17, 57-67 (2009)
PubMed link      E-mail link

Reference Number: 914
Coleman DT, Bigelow R, Cardelli JA. Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation. Mol Cancer Ther. 8, 214-24 (2009)
PubMed link      E-mail link

Reference Number: 927
Wang Y, Yue D, Li K, Liu YL, Ren CS, Wang P. The role of TRPC6 in HGF-induced cell proliferation of human prostate cancer DU145 and PC3 cells. Asian J Androl. 12, 841-52 (2010)
PubMed link      E-mail link

Reference Number: 936
Tu WH, Zhu C, Clark C, Christensen JG, Sun Z. Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer. 10, 556 (2010)
PubMed link      E-mail link

Reference Number: 1010
Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM, Kattan MW, Gerald WL, Vande Woude GF. High expression of the Met receptor in prostate cancer metastasis to bone. Urology. 60, 1113-7 (2002)
PubMed link      E-mail link

Reference Number: 1014
Hay RV, Cao B, Skinner RS, Wang LM, Su Y, Resau JH, Knudsen BS, Gustafson MF, Koo HM, Woude GF, Gross MD. Radioimmunoscintigraphy of human met-expressing tumor xenografts using met3, a new monoclonal antibody. Clin Cancer Res. 9, 3839S-44S (2003)
PubMed link      E-mail link

Reference Number: 1146
Colombel M, Eaton CL, Hamdy F, Ricci E, van der Pluijm G, Cecchini M, Mege-Lechevallier F, Clezardin P, Thalmann G. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. Prostate. 72, 713-20 (2012)
PubMed link      E-mail link

Reference Number: 1172
Hu P, Chu GC, Zhu G, Yang H, Luthringer D, Prins G, Habib F, Wang Y, Wang R, Chung LW, Zhau HE. Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer. PLoS One. 6, e28670 (2011)
PubMed link      E-mail link

Reference Number: 1197
Hwang CI, Choi J, Zhou Z, Flesken-Nikitin A, Tarakhovsky A, Nikitin AY. MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF. Cell Cycle. 10, 3834-40 (2011)
PubMed link      E-mail link

Reference Number: 1246
Virtakoivu R, Pellinen T, Rantala JK, Perälä M, Ivaska J. Distinct roles of AKT isoforms in regulating ß1-integrin activity, migration, and invasion in prostate cancer. Mol Biol Cell. 23, 3357-69 (2012)
PubMed link      E-mail link

Reference Number: 1271
Yu H, Li X, Sun S, Gao X, Zhou D. c-Met inhibitor SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation. Biochem Biophys Res Commun. 427, 659-65 (2012)
PubMed link      E-mail link

Reference Number: 1285
Yoshioka T, Otero J, Chen Y, Kim YM, Koutcher JA, Satagopan J, Reuter V, Carver B, de Stanchina E, Enomoto K, Greenberg NM, Scardino PT, Scher HI, Sawyers CL, Giancotti FG. ß4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest. 123, 682-99 (2013)
PubMed link      E-mail link

Reference Number: 1362
Hagman Z1, Haflidadottir BS, Ansari M, Persson M, Bjartell A, Edsjö A, Ceder Y. The tumour suppressor miR-34c targets MET in prostate cancer cells. Br J Cancer. 109, 1271-8 (2013)
PubMed link      E-mail link

Reference Number: 1442
Ricci E1, Mattei E, Dumontet C, Eaton CL, Hamdy F, van der Pluije G, Cecchini M, Thalmann G, Clezardin P, Colombel M. Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression. Prostate. 73, 1738-46 (2013)
PubMed link      E-mail link

Reference Number: 1463
Liu T1, Mendes DE, Berkman CE. From AR to c-Met: androgen deprivation leads to a signaling pathway switch in prostate cancer cells. Int J Oncol. 43, 1125-30 (2013)
PubMed link      E-mail link

Reference Number: 1516
Hu P1, Chung LW, Berel D, Frierson HF, Yang H, Liu C, Wang R, Li Q, Rogatko A, Zhau HE. Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study. PLoS One. 8, e73081 (2013)
PubMed link      E-mail link

Reference Number: 1580
Steffan JJ, Dykes SS, Coleman DT, Adams LK, Rogers D, Carroll JL, Williams BJ, Cardelli JA. Supporting a role for the GTPase Rab7 in prostate cancer progression. PLoS One. 9, e87882 (2014)
PubMed link      E-mail link

Reference Number: 1597
Ding L, Zhang Z, Liang G, Yao Z, Wu H, Wang B, Zhang J, Tariq M, Ying M, Yang B SAHA triggered MET activation contributes to SAHA tolerance in solid cancer cells. Cancer Lett. 356(2 Pt B), 828-36 (2015)
PubMed link      E-mail link

Reference Number: 1621
Cheng CY, Hwang CI, Corney DC, Flesken-Nikitin A, Jiang L, Oner GM, Munroe RJ, Schimenti JC, Hermeking H, Nikitin AY. miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment. Cell Rep. 6, 1000-7 (2014)
PubMed link      E-mail link

Reference Number: 1719
Wanjala J, Taylor BS, Chapinski C, Hieronymus H, Wongvipat J, Chen Y, Nanjangud GJ, Schultz N, Xie Y, Liu S, Lu W, Yang Q, Sander C, Chen Z, Sawyers CL, Carver BS Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling. Mol Cancer Ther. 14, 278-88 (2015)
PubMed link      E-mail link

Reference Number: 1786
Li Q, Li Q, Nuccio J, Liu C, Duan P, Wang R, Jones LW, Chung LW, Zhau HE. Metastasis initiating cells in primary prostate cancer tissues from transurethral resection of the prostate (TURP) predicts castration-resistant progression and survival of prostate cancer patients. Prostate. 75, 1312-21 (2015)
PubMed link      E-mail link

Reference Number: 1882
Mukai S, Yorita K, Yamasaki K, Nagai T, Kamibeppu T, Sugie S, Kida K, Onizuka C, Tsukino H, Kamimura T, Kamoto T, Kataoka H. Expression of human kallikrein 1-related peptidase 4 (KLK4) and MET phosphorylation in prostate cancer tissue: immunohistochemical analysis. Hum Cell. 28, 133-42 (2015)
PubMed link      E-mail link

Poor Prognosis

Reference Number: 386
Hashem M, Essam T. Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer. J Egypt Natl Canc Inst. 17, 114-20 (2005)
PubMed link      E-mail link

Reference Number: 475
Humphrey PA, Halabi S, Picus J, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer. 4, 269-74 (2006)
PubMed link      E-mail link

Reference Number: 538
Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res. 67, 967-75 2007
PubMed link      E-mail link

Reference Number: 1639
Nishida S, Hirohashi Y, Torigoe T, Nojima M, Inoue R, Kitamura H, Tanaka T, Asanuma H, Sato N, Masumori N. Expression of hepatocyte growth factor in prostate cancer may indicate a biochemical recurrence after radical prostatectomy. Anticancer Res. 35, 413-8 (2015)
PubMed link      E-mail link

Mutation of Met

In vitro studies

Reference Number: 120
Humphrey, P. A. et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147, 386-96 (1995).
PubMed link      E-mail link

Reference Number: 124
Gmyrek, G. A. et al. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol 159, 579-90. (2001).
PubMed link      E-mail link

Reference Number: 125
Nishimura, K. et al. Regulation of invasive potential of human prostate cancer cell lines by hepatocyte growth factor. Int J Urol 5, 276-81 (1998).
PubMed link      E-mail link

Reference Number: 221
Davies, G. et al. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo. Int J Cancer 106:348-54 (2003).
PubMed link      E-mail link

Reference Number: 287
Hall CL, Tsan R, Mugnai G, Mazar A, Radinsky R, Pettaway CA. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA). Prostate 59, 167-76 (2004)
PubMed link      E-mail link

Reference Number: 325
MacDougall CA, Vargas M, Soares CR, Holzer RG, Ide AE, Jorcyk CL, Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c. Prostate 64,139-48 (2005)
PubMed link      E-mail link

Reference Number: 363
Forbs D, Thiel S, Stella MC, Sturzebecher A, Schweinitz A, Steinmetzer T, Sturzebecher J, Uhland K. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol. 27, 1061-70 (2005)
PubMed link      E-mail link

Reference Number: 372
Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene. 25, 2367-78 (2006)
PubMed link      E-mail link

Reference Number: 373
Wells CM, Ahmed T, Masters JR, Jones GE. Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering. Cell Motil Cytoskeleton 62, 180-94 (2005)
PubMed link      E-mail link

Reference Number: 378
Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE. Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am J Pathol. 167, 255-66 (2005)
PubMed link      E-mail link

Reference Number: 379
Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J. 390, 125-36 (2005)
PubMed link      E-mail link

Reference Number: 380
Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett. 579, 1945-50 (2005)
PubMed link      E-mail link

Reference Number: 381
Fan S, Gao M, Meng Q, Laterra JJ, Symons MH, Coniglio S, Pestell RG, Goldberg ID, Rosen EM. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 24, 1749-66 (2005)
PubMed link      E-mail link

Reference Number: 385
Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 66, 794-802 (2006)
PubMed link      E-mail link

Reference Number: 463
Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mansel RE, Mason MD. The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo. Int J Mol Med. 16, 723-8 (2005)
PubMed link      E-mail link

Reference Number: 505
Ye L, Lewis-Russell JM, Davies G, Sanders AJ, Kynaston H, Jiang WG. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. Int J Oncol. 30, 521-9 (2007)
PubMed link      E-mail link

Reference Number: 506
Xu J, Gao M, Fan S, Meng Q, Goldberg ID, Abounader R, Ressom H, Laterra JJ, Rosen EM. Effect of Akt inhibition on scatter factor-regulated gene expression in DU-145 human prostate cancer cells. Oncogene. 26, 2925-38 (2007)
PubMed link      E-mail link

Reference Number: 507
Mukhopadhyay I, Sausville EA, Doroshow JH, Roy KK. Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways. J Biol Chem. 281, 37330-44 (2006)
PubMed link      E-mail link

Reference Number: 508
Maeda A, Nakashiro K, Hara S, Sasaki T, Miwa Y, Tanji N, Yokoyama M, Hamakawa H, Oyasu R. Inactivation of AR activates HGF/c-Met system in human prostatic carcinoma cells. Biochem Biophys Res Commun. 347, 1158-65 (2006)
PubMed link      E-mail link

Reference Number: 509
Tate A, Isotani S, Bradley MJ, Sikes RA, Davis R, Chung LW, Edlund M. Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells. BMC Cancer. 6, 197 (2006)
PubMed link      E-mail link

Reference Number: 551
Davies G, Ablin RJ, Mason MD, Jiang WG. Expression of the prostate transglutaminase (TGase-4) in prostate cancer cells and its impact on the invasiveness of prostate cancer. J Exp Ther Oncol. 6, 257-64 (2007)
PubMed link      E-mail link

Reference Number: 588
Sanders AJ, Parr C, Mason MD, Jiang WG. Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro. Int J Mol Med. 20, 613-9 (2007)
PubMed link      E-mail link

Reference Number: 702
Davies G, Martin TA, Ye L, Lewis-Russell JM, Mason MD, Jiang WG. Phospholipase-C gamma-1 (PLCgamma-1) is critical in hepatocyte growth factor induced in vitro invasion and migration without affecting the growth of prostate cancer cells. Urol Oncol. 26, 386-91 (2008) Epub 2008 Jan 14
PubMed link      E-mail link

Reference Number: 910
Steffan JJ, Williams BC, Welbourne T, Cardelli JA. HGF-induced invasion by prostate tumor cells requires anterograde lysosome trafficking and activity of Na+-H+ exchangers. J Cell Sci. 123(Pt 7), 1151-9 (2010)
PubMed link      E-mail link

Reference Number: 915
Zhang S, Zhau HE, Osunkoya AO, Iqbal S, Yang X, Fan S, Chen Z, Wang R, Marshall FF, Chung LW, Wu D. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer. 9, 9 (2010)
PubMed link      E-mail link

Reference Number: 916
Duhon D, Bigelow RL, Coleman DT, Steffan JJ, Yu C, Langston W, Kevil CG, Cardelli JA. The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells. Mol Carcinog. 49, 739-49 (2010)
PubMed link      E-mail link

Reference Number: 927
Wang Y, Yue D, Li K, Liu YL, Ren CS, Wang P. The role of TRPC6 in HGF-induced cell proliferation of human prostate cancer DU145 and PC3 cells. Asian J Androl. 12, 841-52 (2010)
PubMed link      E-mail link

Reference Number: 930
Ahmed T, Shea K, Masters JR, Jones GE, Wells CM. A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell Signal. 20, 1320-8 (2008)
PubMed link      E-mail link

Reference Number: 941
Bright MD, Garner AP, Ridley AJ. PAK1 and PAK2 have different roles in HGF-induced morphological responses. Cell Signal. 21, 1738-47 (2009)
PubMed link      E-mail link

Reference Number: 942
McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila). 2, 673-82 (2009)
PubMed link      E-mail link

Reference Number: 1057
van Leenders GJ, Sookhlall R, Teubel WJ, de Ridder CM, Reneman S, Sacchetti A, Vissers KJ, van Weerden W, Jenster G. Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS One. 6, e26753 (2011)
PubMed link      E-mail link

Reference Number: 1352
Varkaris A1, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE. Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer. 133, 1536-46 (2013)
PubMed link      E-mail link

Reference Number: 1353
Whale AD1, Dart A, Holt M, Jones GE, Wells CM. PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity. Oncogene. 32, 2114-20 (2013)
PubMed link      E-mail link

Reference Number: 1409
Ucar DA1, Magis AT, He DH, Lawrence NJ, Sebti SM, Kurenova E, Zajac-Kaye M, Zhang J, Hochwald SN. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo. Anticancer Agents Med Chem. 13, 595-602 (2013)
PubMed link      E-mail link

Animal models

Reference Number: 126
Tam, N. N., Chung, S. S., Lee, D. T. & Wong, Y. C. Aberrant expression of hepatocyte growth factor and its receptor, c- Met, during sex hormone-induced prostatic carcinogenesis in the Noble rat. Carcinogenesis 21, 2183-91. (2000).
PubMed link      E-mail link

Reference Number: 326
Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, Cao B, Tsarfaty G, Wang LM, Hay R, Vande Woude GF Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 24, 101-6 (2005)
PubMed link      E-mail link

Reference Number: 345
Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res64, 7962-70 (2004)
PubMed link      E-mail link

Reference Number: 374
Hay RV, Cao B, Skinner RS, Su Y, Zhao P, Gustafson MF, Qian CN, Teh BT, Knudsen BS, Resau JH, Shen S, Waters DJ, Gross MD, Vande Woude GF. Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek). Clin Cancer Res. 11, 7064s-7069s (2005)
PubMed link      E-mail link

Reference Number: 463
Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mansel RE, Mason MD. The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo. Int J Mol Med. 16, 723-8 (2005)
PubMed link      E-mail link

Reference Number: 505
Ye L, Lewis-Russell JM, Davies G, Sanders AJ, Kynaston H, Jiang WG. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. Int J Oncol. 30, 521-9 (2007)
PubMed link      E-mail link

Reference Number: 1581
Chu GC, Zhau HE, Wang R, Rogatko A, Feng X, Zayzafoon M, Liu Y, Farach-Carson MC, You S, Kim J, Freeman MR, Chung LW. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr Relat Cancer. 21, 311-26 (2014)
PubMed link      E-mail link

Reference Number: 1621
Cheng CY, Hwang CI, Corney DC, Flesken-Nikitin A, Jiang L, Oner GM, Munroe RJ, Schimenti JC, Hermeking H, Nikitin AY. miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment. Cell Rep. 6, 1000-7 (2014)
PubMed link      E-mail link

Reference Number: 1650
Eswaraka J, Giddabasappa A, Han G, Lalwani K, Eisele K, Feng Z, Affolter T, Christensen J, Li G. Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer. BMC Cancer. 14, 742 (2014)
PubMed link      E-mail link

Reference Number: 1684
Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik M1, True LD, Morrissey C, Corey E, Montgomery B, Mostaghel E, Clegg N, Coleman I, Brown CM, Schneider EL, Craik C, Simon JA, Bedalov A, Nelson PS. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 4, 1310-25 (201
PubMed link      E-mail link

Reference Number: 1720
Yu Y, Chen Y, Ding G, Wang M, Wu H, Xu L, Rui X, Zhang Z A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts. Biochem Biophys Res Commun. 464, 154-60 (2015)
PubMed link      E-mail link

Therapeutic Development

Reference Number: 221
Davies, G. et al. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo. Int J Cancer 106:348-54 (2003).
PubMed link      E-mail link

Reference Number: 293
Davies G, Watkins G, Mason MD, Jiang WG. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells. Prostate 60, 317-24 (2004)
PubMed link      E-mail link

Reference Number: 345
Shinomiya N, Gao CF, Xie Q, Gustafson M, Waters DJ, Zhang YW, Vande Woude GF. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res64, 7962-70 (2004)
PubMed link      E-mail link

Reference Number: 386
Hashem M, Essam T. Hepatocyte growth factor as a tumor marker in the serum of patients with prostate cancer. J Egypt Natl Canc Inst. 17, 114-20 (2005)
PubMed link      E-mail link

Reference Number: 505
Ye L, Lewis-Russell JM, Davies G, Sanders AJ, Kynaston H, Jiang WG. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. Int J Oncol. 30, 521-9 (2007)
PubMed link      E-mail link

Reference Number: 688
Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, Shariat SF. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res. 14, 7385-90 (2008)
PubMed link      E-mail link

Reference Number: 705
Fan S, Meng Q, Laterra JJ, Rosen EM. Role of Src signal transduction pathways in scatter factor-mediated cellular protection. J Biol Chem. 284, 7561-77 (2009) Epub 2008 Dec 1
PubMed link      E-mail link

Reference Number: 728
Dai Y, Siemann DW. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther. 9, 1554-61 (2010)
PubMed link      E-mail link

Reference Number: 936
Tu WH, Zhu C, Clark C, Christensen JG, Sun Z. Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer. 10, 556 (2010)
PubMed link      E-mail link

Reference Number: 942
McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila). 2, 673-82 (2009)
PubMed link      E-mail link

Reference Number: 1042
Aftab DT, McDonald DM. MET and VEGF: synergistic targets in castration-resistant prostate cancer. Clin Transl Oncol. 13, 703-9 (2011)
PubMed link      E-mail link

Reference Number: 1107
Elnagar AY, Sylvester PW, El Sayed KA. (-)-Oleocanthal as a c-Met inhibitor for the control of metastatic breast and prostate cancers. Planta Med. 77, 1013-9 (2011)
PubMed link      E-mail link

Reference Number: 1123
Chang HY, Kao MC, Way TD, Ho CT, Fu E. Diosgenin suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition by down-regulation of Mdm2 and vimentin. J Agric Food Chem. 59, 5357-63 (2011)
PubMed link      E-mail link

Reference Number: 1209
Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. 20, 1677-84 (2011)
PubMed link      E-mail link

Reference Number: 1222
Dai Y, Siemann DW. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. BMC Cancer. 12, 198 (2012)
PubMed link      E-mail link

Reference Number: 1298
Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol. 63, 309-20 (2013)
PubMed link      E-mail link

Reference Number: 1326
Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 19, 215-24 (2013)
PubMed link      E-mail link

Reference Number: 1510
Nguyen HM, Ruppender N, Zhang X, Brown LG, Gross TS, Morrissey C, Gulati R, Vessella RL, Schimmoller F, Aftab DT, Corey E. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One. 8, e78881 (2013)
PubMed link      E-mail link

Reference Number: 1572
Nguyen HM, Ruppender N, Zhang X, Brown LG, Gross TS, Morrissey C, Gulati R, Vessella RL, Schimmoller F, Aftab DT, Corey E. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One. 8, :e78881 (2013)
PubMed link      E-mail link

Reviews

Reference Number: 785
Knudsen BS, Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res. 91, 31-67 (2004)
PubMed link      E-mail link

Reference Number: 1173
Gallick GE, Corn PG, Zurita AJ, Lin SH. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem. 4, 107-19 (2012)
PubMed link      E-mail link

Reference Number: 1209
Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. 20, 1677-84 (2011)
PubMed link      E-mail link

Reference Number: 1325
Lee RJ, Smith MR. Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J. 19, 90-8 (2013)
PubMed link      E-mail link

Reference Number: 1640
Wozney JL, Antonarakis ES. Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev. 33, 581-94 (2014)
PubMed link      E-mail link

Reference Number: 1652
Ojemuyiwa MA, Madan RA, Dahut WL. Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development. Expert Opin Emerg Drugs. 19, 459-70 (2014)
PubMed link      E-mail link